Products & Services · Total revenues
Prolia — Total revenues
Amgen Prolia — Total revenues decreased by 91.6% to $727M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 91.1%, from $8.15B to $727M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2019
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market adoption, successful commercial execution, or expanded clinical usage, while a decrease may signal increased competition, patent expiration, or market saturation.
Detailed definition
This metric represents the total gross sales generated by a specific therapeutic product line within the company's portf...
Peer comparison
Similar to product-specific revenue reporting in other large-cap pharmaceutical and biotechnology companies, which track the performance of key blockbuster drugs.
Metric ID:
amgn_segment_prolia_total_revenuesHistorical Data
40 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $814M | $6.71B | $803M | $6.85B | $873M | $6.24B | $852M | $6.59B | $922M | $6.65B | $862M | $6.84B | $992M | $6.11B | $927M | $6.99B | $1.03B | $6.9B | $986M | $8.2B | $1.11B | $7.45B | $999M | $8.39B | $1.17B | $8.5B | $1.05B | $9.09B | $1.17B | $8.15B | $1.1B | $9.18B | $1.12B | $9.56B | $1.14B | $9.87B | $1.05B | $8.62B | $727M |
| QoQ Change | — | -87.5% | +723.8% | -88.0% | +752.6% | -87.2% | +614.5% | -86.3% | +673.9% | -86.0% | +621.5% | -87.0% | +693.4% | -85.5% | +515.4% | -84.8% | +653.6% | -85.3% | +571.5% | -85.7% | +731.2% | -86.5% | +572.7% | -86.6% | +739.6% | -86.1% | +629.9% | -87.7% | +769.5% | -87.2% | +599.5% | -86.5% | +735.2% | -87.8% | +751.8% | -88.1% | +766.2% | -89.3% | +717.6% | -91.6% |
| YoY Change | — | — | — | — | — | — | — | — | +1.0% | -85.9% | -0.8% | -87.1% | -0.1% | -85.5% | -2.1% | -85.1% | +5.9% | -84.4% | +3.8% | -85.2% | +19.8% | -83.8% | +22.0% | -83.6% | +20.1% | -83.3% | +23.2% | -84.9% | +10.9% | -85.8% | +9.4% | -85.2% | +9.4% | -86.6% | +12.4% | -86.6% | +8.6% | -88.4% | +5.8% | -91.1% |
Range$727M – $9.87B
CAGR-20.2%
Avg YoY Growth-38.2%
Median YoY Growth-42.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's prolia — total revenues?
- Amgen (AMGN) reported prolia — total revenues of $727M in Q1 2026.
- How has Amgen's prolia — total revenues changed year-over-year?
- Amgen's prolia — total revenues decreased by 91.1% year-over-year, from $8.15B to $727M.
- What does prolia — total revenues mean?
- The total amount of money earned from sales of a specific drug product.